Expanding ketamine’s horizons to treat rare neurological disorders
Pharmaceutical Technology
NOVEMBER 29, 2022
Fox Foundation gave Sanacora a $2 million grant to study the drug’s use for depression in patients with Parkinson’s disease. The Canadian company Awakn Life Sciences is focused on the drug’s use as an treatment of conditions like alcohol use disorder and and behavioral conditions such as addiction.
Let's personalize your content